UP!

News

Carbylan Therapeutics, Inc. (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-04-18 Downgrade JMP Securities Outperform to Market Perform
2016-03-09 Lower Price Target JMP Securities Market Outperform $9.00 to $8.00
2016-03-09 Lower Price Target JPMorgan Chase & Co. Market Outperform $9.00 to $8.00
2016-02-29 Reiterated Rating Wedbush Outperform $14.00
2016-02-02 Reiterated Rating Wedbush Outperform $21.00 to $14.00
2016-02-02 Downgrade Leerink Swann Outperform to Market Perform $15.00 to $1.80
2015-12-28 Reiterated Rating Wedbush Buy
2015-12-22 Reiterated Rating Wedbush Outperform $21.00
2015-10-02 Initiated Coverage JMP Securities Outperform $13.00
2015-08-12 Reiterated Rating Wedbush Buy $21.00
2015-08-12 Reiterated Rating Leerink Swann Buy $16.00
2015-07-16 Reiterated Rating Wedbush Buy $21.00
2015-06-09 Reiterated Rating Northland Securities Outperform $20.00
2015-06-09 Reiterated Rating Wedbush Outperform $21.00
2015-05-22 Reiterated Rating Wedbush Outperform $21.00
2015-05-14 Initiated Coverage Northland Securities Outperform $20.00
2015-05-04 Initiated Coverage Wedbush Outperform $21.00
2015-05-04 Initiated Coverage Leerink Swann Outperform $16.00
2016-04-18 Downgrade JMP Securities Outperform to Market Perform
2016-03-09 Lower Price Target JMP Securities Market Outperform $9.00 to $8.00
2016-03-09 Lower Price Target JPMorgan Chase & Co. Market Outperform $9.00 to $8.00
2016-02-29 Reiterated Rating Wedbush Outperform $14.00
2016-02-02 Reiterated Rating Wedbush Outperform $21.00 to $14.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In CBYL 0 funds of 2184 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments